Go Deep
Pulse Biosciences, Inc.
Pulse Biosciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 5,215 | -41.1 | 34.79 | 0.07 | 4,622.64 |
| Oct 2026 | 6,201 | -39.3 | 33.20 | 0.07 | 4,397.97 |
| Oct 2026 | 6,523 | -40.7 | 32.68 | 0.07 | 4,329.27 |
| Oct 2026 | 7,041 | -37.7 | 31.85 | 0.07 | 4,208.19 |
| Oct 2026 | 5,655 | -40.3 | 34.08 | 0.07 | 4,508.52 |
| Oct 2026 | 4,194 | -43.1 | 36.44 | 0.07 | 4,820.47 |
| Oct 2026 | 3,985 | -43.5 | 36.78 | 0.07 | 4,853.01 |
| Oct 2026 | 3,376 | -44.6 | 37.76 | 0.07 | 4,972.51 |
| Oct 2026 | 3,225 | -44.9 | 38.01 | 0.07 | 5,025.35 |
Pulse Biosciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 434,000.0 | 401,000.0 | 264,000.0 | 86,000.0 |
| Net Profit | -24,657,000.0 | -18,581,000.0 | -17,433,000.0 | -19,385,000.0 |
| EPS | -0.4 | -0.3 | -0.3 | -0.3 |
Pulse Biosciences, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 350,000.0 | 0.0 | 0.0 | 700,000.0 | — |
| Net Profit | -72,781,000.0 | -53,585,000.0 | -42,210,000.0 | -58,505,000.0 | — |
| EPS | -1.1 | -0.9 | -0.8 | -1.7 | — |
Pulse Biosciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 94,539,000.0 | 132,460,000.0 | 59,154,000.0 | 77,877,000.0 | — |
| Total Liabilities | 13,883,000.0 | 17,598,000.0 | 14,794,000.0 | 80,125,000.0 | — |
| Total Equity | 80,656,000.0 | 114,862,000.0 | 44,360,000.0 | -2,248,000.0 | — |
Owes vs Owns
Pulse Biosciences, Inc. owed $0.14 for every $1 it owned in Jun 2026, down from $1.03 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.14× | 0.15× | 0.13× | 0.25× | 1.03× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Pulse Biosciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 85.4%Fixed assets (tangible) 7.5%Intangible assets 3.6%Other assets 3.1%
How it's funded — Dec 2025
Short-term debt 1.7%Long-term debt 6.3%Payables 2.9%Other liabilities 3.8%Shareholders' equity 85.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 80.7 | 118.0 | 44.4 | 61.1 |
| Receivables | 0.3 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.1 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 7.1 | 8.3 | 8.8 | 10.0 |
| Intangible assets | 3.4 | 4.0 | 4.7 | 5.3 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 3.0 | 2.1 | 1.3 | 1.4 |
| Liabilities & equity | ||||
| Short-term debt | 1.6 | 1.4 | 1.1 | 0.9 |
| Long-term debt | 6.0 | 7.5 | 8.1 | 65.0 |
| Payables | 2.8 | 1.7 | 1.8 | 1.6 |
| Other liabilities | 3.6 | 7.0 | 3.8 | 12.6 |
| Shareholders' equity | 80.7 | 114.9 | 44.4 | -2.2 |
| Net tangible assets | 77.3 | 110.9 | 39.7 | -7.6 |
Pulse Biosciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -54,122,000.0 | -36,343,000.0 | -33,041,000.0 | -47,013,000.0 | — |
| Investing Activities | -335,000.0 | -125,000.0 | -121,000.0 | -401,000.0 | — |
| Financing Activities | 17,154,000.0 | 110,141,000.0 | 16,388,000.0 | 79,939,000.0 | — |